The effect of interferon in the therapy of severe coronavirus infection.
ARDS
COVID-19
inflammatory markers
interferon
treatment
Journal
Journal of education and health promotion
ISSN: 2277-9531
Titre abrégé: J Educ Health Promot
Pays: India
ID NLM: 101593794
Informations de publication
Date de publication:
2023
2023
Historique:
received:
10
03
2021
accepted:
07
06
2022
medline:
3
7
2023
pubmed:
3
7
2023
entrez:
3
7
2023
Statut:
epublish
Résumé
So far, several protocols have been used for the treatment of coronavirus disease-2019 (COVID-19). In this study, we aimed to study the effect of interferon on the treatment of hypoxemia caused by COVID-19. This was a quasi-experiment with a nonequivalent group design. All participants were admitted to Shahid Beheshti Hospital, Qom province. In total, 60 patients were enrolled in the study, and inclusion criteria were age over 18 years, positive PCR test result, pulmonary involvement in computed tomography (CT) scan, and SpO The mean ± standard deviation (SD) age of patients was 63 ± 16.12 years and 43.3% were male. In terms of outcome variables, 20% of patients in the intervention group and 53.3% of subjects in the control group died and this difference was significant ( Based on the results of this study, the use of interferon in the treatment of COVID-19 can improve health and reduce the severity of the disease and mortality.
Sections du résumé
BACKGROUND
BACKGROUND
So far, several protocols have been used for the treatment of coronavirus disease-2019 (COVID-19). In this study, we aimed to study the effect of interferon on the treatment of hypoxemia caused by COVID-19.
MATERIALS AND METHODS
METHODS
This was a quasi-experiment with a nonequivalent group design. All participants were admitted to Shahid Beheshti Hospital, Qom province. In total, 60 patients were enrolled in the study, and inclusion criteria were age over 18 years, positive PCR test result, pulmonary involvement in computed tomography (CT) scan, and SpO
RESULTS
RESULTS
The mean ± standard deviation (SD) age of patients was 63 ± 16.12 years and 43.3% were male. In terms of outcome variables, 20% of patients in the intervention group and 53.3% of subjects in the control group died and this difference was significant (
CONCLUSION
CONCLUSIONS
Based on the results of this study, the use of interferon in the treatment of COVID-19 can improve health and reduce the severity of the disease and mortality.
Identifiants
pubmed: 37397116
doi: 10.4103/jehp.jehp_332_21
pii: JEHP-12-129
pmc: PMC10312544
doi:
Types de publication
Journal Article
Langues
eng
Pagination
129Informations de copyright
Copyright: © 2023 Journal of Education and Health Promotion.
Déclaration de conflit d'intérêts
There are no conflicts of interest.
Références
Front Immunol. 2020 May 15;11:1061
pubmed: 32574262
JAMA. 2020 Apr 14;323(14):1406-1407
pubmed: 32083643
Int Immunopharmacol. 2020 Nov;88:106903
pubmed: 32862111
J Exp Med. 2020 May 4;217(5):
pubmed: 32289152
Infect Dis Poverty. 2020 Mar 17;9(1):29
pubmed: 32183901
JAMA. 2020 May 12;323(18):1824-1836
pubmed: 32282022
Nat Rev Cardiol. 2020 May;17(5):259-260
pubmed: 32139904
Antimicrob Agents Chemother. 2020 Aug 20;64(9):
pubmed: 32661006
Cell Host Microbe. 2020 Sep 9;28(3):455-464.e2
pubmed: 32707096
J Autoimmun. 2020 May;109:102433
pubmed: 32113704
Trials. 2020 Nov 23;21(1):939
pubmed: 33225960
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
Thromb Haemost. 2022 Jan;122(1):131-141
pubmed: 33865239